{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-005674","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2023-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.988169+00:00","generated_at":"2026-06-20T16:51:59.415729+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Madrigal reports supportive MAESTRO-NASH consensus read; NASH resolution and fibrosis improvement remain significant","bullets":["Consensus read: NASH resolution 24% (80mg) and 28% (100mg) vs 8% placebo (p<0.0001).","Fibrosis improvement ≥1 stage: 24% (80mg) and 26% (100mg) vs 12% placebo (p<0.0001).","Analysis used digitized biopsies when two pathologists' scores disagreed on primary endpoints.","Results consistent with primary analysis announced Dec 19, 2022; trial continues for up to 54 months.","Data presented at NASH-TAG Conference on Jan 6, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-005674","json":"https://secwatch.observer/filing/0001193125-23-005674.json","markdown":"https://secwatch.observer/filing/0001193125-23-005674.md","text":"https://secwatch.observer/filing/0001193125-23-005674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523005674/0001193125-23-005674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523005674/d436279d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:51:59.415729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}